

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

DENNLER et al.

Serial No.: 09/605,534

Filed: August 28, 2000

For: METHOD OF SCREENING THERAPEUTIC AGENTS

* * * * *

Atty. Ref.: 1430-245

Group Art Unit: 1642

Examiner: Rawlings, S.

November 6, 2001 NOV 08 2001

TECH CENTER 1600/2900

RESPONSE

Hon. Commissioner of Patents
and Trademarks
Washington, DC 20231

Sir:


In response to the Notice to Comply dated October 10, 2001, attention is directed to the fact that paper and computer readable copies of the Sequence Listing were submitted in this case, together with a Response to Notice to Comply on December 14, 2000. Further copies of the Response, Sequence Listing (paper and computer readable copies) and postcard receipt are submitted herewith.

An early and favorable Action on the merits is awaited.

Respectfully submitted,

NIXON & VANDERHYE, P.C.

By


Mary J. Wilson
Reg. No. 32,955

MJW:tat

1100 North Glebe Road. 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 1430-245

DENNLER et al.

C# M#

Serial No. 09/601,534

Group Art Unit: 1642

Filed: August 28, 2000

Examiner: Rawlings, S.

Date: November 6, 2001

Title: METHOD OF SCREENING THERAPEUTIC AGENTS

Assistant Commissioner for Patents
Washington, DC 20231

RECEIVED

NOV 08 2001

TECH CENTER 1600/2900

Sir:

RESPONSE TO NOTICE TO COMPLY

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby incorporated by reference and the signature below serves as the signature to the attachment in the absence of any other signature thereon.

Fees are attached as calculated below:

Total effective claims after amendment	0	minus highest number		
previously paid for	20	(at least 20) =	0 x \$ 18.00	\$ 0.00

Independent claims after amendment	0	minus highest number		
previously paid for	3	(at least 3) =	0 x \$ 84.00	\$ 0.00

If proper multiple dependent claims now added for first time, add \$280.00 (ignore improper)	\$ 0.00
----------------------------------------------------------------------------------------------	---------

Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s) (\$110.00/1 month; \$400.00/2 months; \$920.00/3 months)	\$ 0.00
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------

Terminal disclaimer enclosed, add \$ 110.00	\$ 0.00
---------------------------------------------	---------

<input type="checkbox"/> First/second submission after Final Rejection pursuant to 37 CFR 1.129(a) (\$740.00)	\$ 0.00
<input type="checkbox"/> Please enter the previously unentered, filed	
<input type="checkbox"/> Submission attached	

Subtotal	\$ 0.00
-----------------	---------

If "small entity," then enter half (1/2) of subtotal and subtract	-\$ 0.00
-------------------------------------------------------------------	----------

<input type="checkbox"/> Applicant claims "small entity" status.	<input type="checkbox"/> Statement filed herewith
------------------------------------------------------------------	---------------------------------------------------

Rule 56 Information Disclosure Statement Filing Fee (\$180.00)	\$ 0.00
----------------------------------------------------------------	---------

Assignment Recording Fee (\$40.00)	\$ 0.00
------------------------------------	---------

Other:	0.00
--------	------

TOTAL FEE ENCLOSED	\$ 0.00
---------------------------	---------

The Commissioner is hereby authorized to charge any deficiency in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor
Arlington, Virginia 22201-4714
Telephone: (703) 816-4000
Facsimile: (703) 816-4100
MJW:tat

NIXON & VANDERHYE P.C.
By Atty: Mary J. Wilson, Reg. No. 32,955

Signature: Mary J. Wilson

RECEIVED


NOV 08 2001

TECH CENTER 1600/2900

Serial No.: 09/601,534
Applicant: DENNLER et al
Title: METHOD OF SCREENING
THERAPEUTIC AGENTS


Atty: MJW
Date: 12-14-2000
Client: GLAXO WELLCOME
Ref: 1430-245

☒ Amendment RESPONSE TO NOTICE TO COMPLY
☐ Pages Specification
☐ Claims
☐ Sheets Drawings: Formal _____
Informal _____
☐ Declaration (_____ Pages)
☐ Assignment
☐ Priority Document
☐ Base Issue Fee Transmittal
☐ Fee (Check)



Other: NOTICE TO COMPLY, SEQUENCE LISTING,
DISK

Notice to Comply



Application No.

09/601,534

Examiner

Stephen L. Rawlings, Ph.D.

Applicant(s)

DENNLER ET AL NOV 08 2001

Art Unit

1642

RECEIVED

TECH CENTER 1600/2900

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY